Retatrutide vs. tirzepatide at product level
The first row is the one that matters. Everything below it is a comparison between something you can be prescribed and something you cannot.
Swipe horizontally to compare →
| Detail | Tirzepatide | Retatrutide |
|---|---|---|
| Regulatory status | FDA-approved | Investigational, not approved |
| Available by prescription | Yes | No |
| Receptor action | GIP and GLP-1 | GIP, GLP-1 and glucagon |
| Sold as | Zepbound, Mounjaro | Nothing lawfully sold to consumers |
| Can be compounded | Compounded preparations exist and are not approved products | No. FDA says it cannot be used in compounding |
Table source:FDA guidance on unapproved GLP-1 products
01
Only one of these is a medication you can be prescribed
Tirzepatide is approved by the FDA and is sold as Zepbound for weight management and Mounjaro for type 2 diabetes. A licensed clinician evaluates you and writes for it.
Retatrutide has reported trial results and is not approved. There is no lawful route to a retatrutide prescription in the United States today, and the FDA has stated it cannot be used in compounding↗. Anything offered for sale under that name is outside the approval system entirely.
02
What the third receptor is about
Tirzepatide acts on two receptors, GIP and GLP-1. Retatrutide is being studied as a triple agonist, adding glucagon receptor activity to those two.
That is a genuine difference in design and it is why the trial results have drawn attention. It is not a difference you can act on. Acting on it means buying an unapproved drug from an unregulated seller.
03
How to recognize an offer that should be refused
Sellers describe unapproved retatrutide as research-grade, research-use-only, or compounded. None of those descriptions make it a treatment. The last describes something the FDA has said cannot lawfully be done with this ingredient.
A legitimate weight-care clinic will not offer it. If a program does, that tells you what to conclude about the rest of what it offers.
- Marketed as research-grade or research-use-only: not a medicine for human use.
- Sold as compounded retatrutide: FDA says the ingredient cannot be used in compounding.
- Sold without a clinician evaluation: outside the prescription system altogether.
Common questions
Answers to clarify the comparison
Is retatrutide better than tirzepatide?
Can I get retatrutide from a compounding pharmacy?
When will retatrutide be available?
Primary sources
Read the official material behind this page
- FDA: concerns with unapproved GLP-1 drugs used for weight loss
- FDA Zepbound prescribing information
- NIDDK: prescription medications to treat overweight and obesity
Health information is educational and does not diagnose, determine eligibility, or replace product labeling and care from a qualified professional.


